DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to...
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors...
Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC...
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving...
– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by...
Plenary Presentation to be Followed by Poster Presentation Highlighting HLD-0915 Clinical DataBOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics...
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States...
FDA agrees with Phase 2b/3 clinical design, including primary endpoint and development approach, providing clear regulatory pathway to conduct two...
SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical...
New Offerings Bring Millions Affordable Healthcare Solutions During Open Enrollment SeasonDRAPER, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc....
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated...
DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical...
LOUISVILLE, Ky., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a national leader in musculoskeletal (MSK) care, today announced its...
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy...
Late breaking session to feature results from the successful PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract...
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®...
Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the...
Award recognizes technology breakthroughs that promise to help define the future of their industriesNEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE)...
Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone...
Notification has no immediate effect on the Company’s listing or day-to-day operationsROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone...